Prognostic impact of extracellular volume fraction derived from equilibrium contrast-enhanced CT in HCC patients receiving immune checkpoint inhibitors

被引：0

作者：

Xiaona Fu ^{[1
]}

Yusheng Guo ^{[2
]}

Kailu Zhang ^{[1
]}

Zhixuan Cheng ^{[2
]}

Chanyuan Liu ^{[1
]}

Yi Ren ^{[2
]}

Lianwei Miao ^{[1
]}

Weiwei Liu ^{[2
]}

Shanshan Jiang ^{[1
]}

Chen Zhou ^{[2
]}

Yangbo Su ^{[1
]}

Lian Yang ^{[2
]}

机构：

[1] Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

[2] Hubei Key Laboratory of Molecular Imaging, Wuhan

来源：

Scientific Reports | / 15卷 / 1期

基金：

中国国家自然科学基金;

关键词：

Extracellular volume fraction; Hepatocellular carcinoma; Immune checkpoint inhibitors; Prognosis;

D O I：

10.1038/s41598-025-97677-x

中图分类号：

学科分类号：

摘要：

This study aimed to investigate whether extracellular volume (ECV) fraction derived from equilibration contrast-enhanced computed tomography (CECT) affects prognosis in HCC patients receiving ICIs. This retrospective study ultimately included 211 HCC patients undergoing ICIs, of whom 60 were included in an internal validation to assess the reproducibility of the results. Baseline unenhanced and equilibrated CECT were used to measure CT values of the tumor, liver and aorta, which were combined with hematocrit to calculate the ECV fraction. Correlation analysis was used to investigate the association between tumor ECV and liver ECV fractions. The effects of clinical variables and ECV fraction on progression-free survival (PFS) and overall survival (OS) were evaluated using Cox proportional hazards models and Kaplan-Meier curves. Of these 151 patients, tumor ECV fraction positively correlated with liver ECV fraction. In the Lower tumor ECV group, PFS (5.6 vs. 7.6 months) and OS (10.5 vs. 15.5 months) were notably shorter than in the Higher tumor ECV group, while no significant differences were found between the Higher and Lower liver ECV groups. Furthermore, the multivariable Cox regression model demonstrated that higher tumor ECV fraction level was an independent protective factor for PFS and OS (all P < 0.001). Internal validation cohort preliminary demonstrated reproducibility of results. The tumor ECV fraction is expected to become a routine indicator before ICIs therapy for HCC patients in contrast to liver ECV fraction, contributing to their subsequent management. © The Author(s) 2025.

引用

共 44 条

[1] Sangro B., Sarobe P., Hervas-Stubbs S., Melero, I. Advances in immunotherapy for hepatocellular carcinoma, Nat. Rev. Gastroenterol. Hepatol, 18, pp. 525-543, (2021)
[2] Sung H., Et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin, 71, pp. 209-249, (2021)
[3] Wang W., Wei C., Advances in the early diagnosis of hepatocellular carcinoma, Genes Dis, 7, pp. 308-319, (2020)
[4] Foerster F., Gairing S.J., Ilyas S.I., Galle P.R., Emerging immunotherapy for HCC: A guide for hepatologists, Hepatology, 75, pp. 1604-1626, (2022)
[5] Cheng A.L., Hsu C., Chan S.L., Choo S.P., Kudo M., Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma, J. Hepatol, 72, pp. 307-319, (2020)
[6] Peters S., Kerr K.M., Stahel R., PD-1 Blockade in advanced NSCLC: A focus on pembrolizumab, Cancer Treat. Rev, 62, pp. 39-49, (2018)
[7] Deutsch J.S., Et al., Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma, Cell. Rep. Med, 4, (2023)
[8] Pinter M., Jain R.K., Duda D.G., The current landscape of immune checkpoint Blockade in hepatocellular carcinoma: A review, JAMA Oncol, 7, pp. 113-123, (2021)
[9] Gao R., Et al., Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data, J. Hematol. Oncol, 14, (2021)
[10] Karamanos N.K., Et al., A guide to the composition and functions of the extracellular matrix, Febs J, 288, pp. 6850-6912, (2021)

← 1 2 3 4 5 →